Why Arcutis Biotherapeutics, Inc.’s (ARQT) Stock Is Down 5.62%
As of Wednesday, September 23, Arcutis Biotherapeutics, Inc.’s ARQT share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. ARQT
$25.16
-0.13
-0.51%
October 2, 2026 4:00:00 PM
EST
Volume: 1,778,421
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Commentary & Analysis
Why Arcutis Biotherapeutics, Inc.’s (ARQT) Stock Is Down 5.07%
As of Thursday, September 17, Arcutis Biotherapeutics, Inc.’s ARQT share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Arcutis Biotherapeutics, Inc.’s (ARQT) Stock Is Up 6.64%
As of Wednesday, September 16, Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 6.64%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Arcutis Biotherapeutics, Inc.'s Q3 Earnings
Arcutis Biotherapeutics, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (ARQT) missed or beat analyst's expectations.Tudor Pop
Is Arcutis Biotherapeutics, Inc. (ARQT) Overvalued?
We dive into why Arcutis Biotherapeutics, Inc. (ARQT) could be considered overvalued on 2026-07-31, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,162.4 | $250.1 | 61% |
|
| Shares Out (Mil) | 135.9 | 54.0 | 69% |
|
| Institutional Ownership | 98.8% | 93.1% | 82% |
|
| Float (Mil) | 93.8 | 41.4 | 59% |
|
| Beta | 1.50 | 0.95 | 82% |
|
| Avg Daily Volume (000s) | 2,328 | 661 | 83% |
|
| Price Change (52-week) |
27.3% | 49.5% | 73% |
|
| Growth | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | 34.7% | (10.1%) | 88% |
|
| EPS (5yr) | 49.3% | 15.8% | 93 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.4%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.172 | $0.430 | $1.360 | |
| Month Ago EPS | $0.158 | $0.412 | $1.303 | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.076 | $0.165 | $1.127 | |
| Year/Year Chg | 56.4% | (438.6%) | (1,818%) | |
| Financials | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $464 | $37 | 40% |
|
| Net Income (TTM) (Mil) | $29 | ($44) | 51% |
|
| EPS (TTM) | $0.221 | ($1.600) | 47% |
|
| Operating Cash Flow (TTM) (Mil) | $39 | ($33) | 45% |
|
| Net Cash Flow (TTM) (Mil) | ($39) | $2 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $107 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $3,139 | $175 | 56% |
|
| Valuation | ARQT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.30 | 2.36 | 93% |
|
| P/E | 117.0 | 18.9 | 94% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.4 | 1.0 | 74% |
|
| Ratios | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.1% | 67.3% | 94% |
|
| Net Margin | 6.1% | (74.8%) | 52% |
|
| ROA | 6.8% | (47.6%) | 78% |
|
| ROE | 15.9% | (54.9%) | 73% |
|
| Liabilities to Assets | 54.8% | 29.3% | 47% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 10/2/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
